

ORIGINAL

The influence of sex and gender factors on the modulation of vulnerability to addictions: A narrative review

La influencia de los factores de sexo y género en la modulación de la vulnerabilidad a las adicciones: Una revisión narrativa

CRISTINA RIUS^{*,**}; RUT LUCAS-DOMINGUEZ^{*,**}; JUDIT TIRADO-MUÑOZ^{***,****}; LYDIA GARCIA- GOMEZ^{**}; LAURA PRIETO-ARENAS^{*****}; ANTONIO VIDAL-INFER^{*,**},^{*****}.

^{*}Department of History of Science and Information Science, School of Medicine and Dentistry, University of Valencia, Valencia, Spain.

^{**}UISYS, Joint Research Unit, University of Valencia, Valencia, Spain. Associated Unit Research Institute for Higher Education and Science (INAEU) UC3M-UAM, Spain.

^{***}Department of Psychology, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

^{****}Research Network in Primary Care of Addictions (RIAPAd), Spain.

^{*****}Unidad de Salud Mental. Hospital General Obispo Polanco de Teruel, Spain.

Abstract

This narrative review identifies the sex- and gender-related factors that influence individual vulnerability to developing addictive disorders. Addiction arises from the complex interaction between neurobiological and psychosocial factors. Sex-based brain dimorphisms, shaped by genetic, hormonal, and epigenetic influences, lead to differences in neural circuits involved in reward, emotional regulation, and executive functioning. Pharmacokinetic differences, such as higher blood alcohol levels, faster nicotine metabolism, and slower μ -opioid receptor internalization in women, contribute to earlier medical complications and faster addiction progression. Gender, understood as a system of socially constructed roles and expectations, further modulates these vulnerabilities. Traditional masculine norms are associated with higher substance use, while certain aspects of femininity may increase risk (e.g., emotional repression or partner dependence) or serve as protective factors through help-seeking behavior. Sexual and gender minorities experience the most significant disparities. Lesbian and bisexual women show the highest rates of substance use disorders; gay and bisexual men report greater illicit drug use; and bisexual individuals consistently display the highest overall risk. Transgender and non- binary populations exhibit increased prevalence of tobacco, stimulant, and chemsex-related substance use, often as a response to minority stress and exclusion from cisnormative care systems. Psychiatric comorbidity affects 50–80% of cases. Women show higher rates of anxiety, trauma histories, and adverse clinical outcomes. Many face “triple stigma” due to their gender, mental health condition, and substance use. Addressing these disparities requires an intersectional, gender-informed, and culturally competent approach to prevention, diagnosis, and treatment.

Keywords: vulnerability, sex differences, gender norms, substance-use disorder, dual diagnosis, sexual and gender minorities

Resumen

En este trabajo se ha realizado una revisión narrativa que identifica los factores asociados al sexo y al género que influyen en la vulnerabilidad frente al desarrollo de un trastorno adictivo. Las adicciones surgen de la interacción entre factores neurobiológicos y psicosociales. Los dimorfismos cerebrales según el sexo, mediados por factores genéticos, hormonales y epigenéticos, generan diferencias en los circuitos implicados en la recompensa, la regulación emocional y las funciones ejecutivas. Las diferencias farmacocinéticas, como mayores niveles sanguíneos de alcohol, metabolismo más rápido de la nicotina y una internalización más lenta de los receptores μ -opioides en mujeres, contribuyen a una progresión más rápida y a la aparición más temprana de complicaciones médicas. El género, entendido como un sistema de roles y normas socialmente construidos, modula estas vulnerabilidades. Las normas masculinas tradicionales se asocian a mayor consumo, mientras que algunos aspectos de la feminidad pueden actuar como factores de riesgo o protección. Las minorías sexuales y de género presentan las mayores disparidades. Las mujeres lesbianas y bisexuales tienen las tasas más elevadas de trastornos por uso de sustancias; los hombres gays y bisexuales informan mayor consumo de drogas ilícitas; las personas bisexuales muestran el mayor riesgo global. Las poblaciones trans y no binarias presentan prevalencias más altas de consumo de tabaco, estimulantes y sustancias asociadas al chemsex, muchas veces como respuesta al estrés de minoría y a sistemas de salud cisnormativos. La comorbilidad psiquiátrica afecta al 50–80 % de los casos. Abordar estas desigualdades requiere un enfoque interseccional, sensible al género y culturalmente competente.

Palabras clave: vulnerabilidad, diferencias según el sexo, normas de género, trastorno por consumo de sustancias, patología dual, minorías sexuales y de género

■ Received: May 2025; Accepted: September 2025.

■ ISSN: 0214-4840 / E-ISSN: 2604-6334

■ Send correspondence to:

Antonio Vidal Infer. Department of History of Science and Information Science, School of Medicine and Dentistry, University of Valencia. Avda. Blasco Ibañez, 15, 46010. Valencia (Spain). Email: Antonio.Vidal-Infer@uv.es

Addiction is a complex phenomenon shaped by biological, psychological, and social factors. Within this framework, vulnerability emerges as a key concept for explaining why some individuals develop pathological dependence while others do not, even with similar patterns. This transition is mediated by individual characteristics such as impulsivity, sensation-seeking, or the presence of affective and anxiety disorders.

These traits can predispose individuals to use substances as a means of regulating negative emotions, coping with stress, or meeting unmet psychological needs.

Biological sex and socially constructed gender profoundly shape the responses of brain and body to addictive stimuli. Incorporating these dimensions into research is therefore essential for accurately pinpointing risk factors and crafting truly effective prevention and treatment strategies. Informed by a targeted search of the scientific literature from the past two decades in Web of Science and Scopus, this article delineates the principal sex/gender related determinants of vulnerability, ranging from biological and social factors to specific concerns, such as abuse, trauma, gender-nonconforming populations and co-occurring disorders (dual diagnosis).

Modulation Of Vulnerability To Addictions By Sex And Gender From A Biological Perspective

Scientific literature has shown sexual dimorphisms in the nervous system (NS) that can influence vulnerability to addictions. Specifically, genetic, epigenetic, and hormonal differences during brain development and organization lead to variations in the neural circuits involved in reward processing, emotion, and executive functions in men and women (McHugh et al., 2018), triggering divergent responses to the same substances of abuse.

At the neuroanatomical and functional level, neuroimaging studies in people with substance-use disorder (SUD) reveal alterations in regions such as the striatum—particularly the nucleus accumbens (NAc), which integrates pleasure and motivation—the amygdala (associates stimuli with reward or punishment), the hippocampus (contextual memory of rewarding experiences), the insula (regulates craving), and the corpus callosum (connects the cerebral hemispheres, integrating cognitive and emotional functions). These alterations differ between sexes, although further research is needed to refine these findings (Cornish & Prasad, 2021; Rando et al., 2013), and they also vary depending on the substance consumed. In alcohol-use disorder (AUD), men show volume reductions in these areas compared with healthy controls, whereas women with AUD exhibit enlarged volumes (Sawyer et al., 2017; Sawyer et al., 2018; Zahr et al., 2020). Studies of heavy alcohol consumption

in adolescence and early adulthood likewise reveal sex-specific imaging differences in the prefrontal, striatal, and medial-temporal regions: young women drinkers have greater volumes than healthy women, while men show the opposite pattern with volume loss (Kvamme et al., 2016; Morris et al., 2019; Pfefferbaum et al., 2016). Similarly, Nie et al. (2021) found that male chronic methamphetamine users in abstinence had smaller hippocampi than healthy men, whereas no such structural effects were observed in women. Conversely, significant gray-matter reductions were detected in women with stimulant addiction, cocaine and/or amphetamines, after prolonged abstinence, but not in men (Regner et al., 2015). Collectively, these findings suggest sex-specific neuroplastic adaptations that may underlie the differing clinical manifestations of addiction (Cornish & Prasad, 2021).

Regarding neurochemical sex differences in reward, the mesocorticolimbic dopaminergic system is most prominent, with the ventral tegmental area (VTA) as the main source of dopaminergic neurons. Dopamine (DA) release in the NAc is central to reward; drugs inhibit its reuptake as an artificial reinforcement. Human and rodent studies reveal that men and women activate dopaminergic reward circuits differently, not only in magnitude but also neuroanatomically, with distinct responses in the ventral NAc versus dorsal striatum (Copenhaver & LeGates, 2024; Cosgrove et al., 2014; Gillies et al., 2014). This neural pattern may underlie the sex difference in escalation of use leading to addiction. Cosgrove et al. (2014) showed that men activate the ventral striatum more intensely when smoking, consistent with cigarette reinforcement, whereas women smoke more for emotional regulation and cue-reactivity. PET imaging further demonstrated that men exhibit a rapid, consistent dopaminergic response in the ventral striatum, while women respond more rapidly in the dorsal striatum (putamen). In cocaine addiction, women tend to progress faster to habitual use, partly due to lower DA release in the ventral striatum, prompting higher intake to achieve similar effects. Enhanced dopaminergic activity in the dorsolateral striatum may, in turn, facilitate the transition to compulsive use in women (Becker & Chartoff, 2019).

About the effects of sex on the endocrine system and how this influences vulnerability, there is extensive literature that examines how estradiol interacts with the mesolimbic reward circuit to heighten women's vulnerability to drug addiction. Sex hormones, such as estrogens, progesterone, and androgens, strongly modulate brain and behavior, including reward responses. Estradiol enhances drug reinforcement by increasing drug-induced DA release in mesolimbic and striatal pathways. Consequently, female rats display stronger drug-motivated behaviors when estradiol levels are high (proestrus/estrus, analogous to late follicular/ovulation in women) (Becker, 2016). Hormonal fluctuations across the

estrus/menstrual cycle can alter both the rate of addiction acquisition and the strength of drug reinforcement (Kokane & Perrotti, 2020; Sardari et al., 2024). Estradiol elevates the rewarding, reinforcing properties of opioids, cocaine, and amphetamines, thereby affecting vulnerability (Kokane & Perrotti, 2020). By contrast, progesterone often counters estradiol. In women who use cocaine, high progesterone levels and its derivatives such as allopregnanolone (e.g., during the luteal phase or with certain contraceptives) associate with reduced craving and consumption (Peart et al., 2022). These findings have spurred research into progesterone analogues as potential relapse-reduction treatments for female psychostimulant users: progesterone has shown efficacy in lowering cocaine craving and arousal in women, though not in men (Fox et al., 2013).

Hormonal modulation extends to drug metabolism. Estrogens and progestogens partly account for higher peak plasma cocaine levels in women than in men given the same dose (Peart et al., 2022). Conversely, women metabolize nicotine more rapidly, particularly those on oral contraceptives (Allen et al., 2019; Berlin et al., 2007). Such pharmacokinetic variations contribute to sex differences in addiction vulnerability (Thibaut, 2018). Women also reach higher blood-alcohol concentrations than men after equivalent consumption due to lower lean body mass and reduced gastric alcohol-dehydrogenase activity (Komáreková et al., 2013). Consequently, women may suffer alcohol-induced hepatic and cardiac damage at lower doses and shorter durations—a “clinical telescoping” effect (McHugh et al., 2018). Many medical complications of addiction—neuropathy, alcohol-related cognitive decline, cardiomyopathy, cirrhosis, and substance-induced mood disorders—appear earlier and after lower cumulative exposure in women (Trillo et al., 2012). With opioids, morphine shows slower μ -opioid-receptor activation and clearance in women, often necessitating higher doses and making them more prone to hyperalgesia and rapid tolerance, potentially requiring larger opioid doses for equivalent analgesia (Fullerton et al., 2018).

In men, a more stable androgen-dominated hormonal profile exists, and its influence on addictive behavior is less studied than that of estrogens and progesterone. Testosterone and derivatives can modulate dopaminergic and glutamatergic transmission, and some evidence links high androgen levels to greater risk-taking and sensation-seeking, facilitating initiation of use. However, direct testosterone effects on drug reinforcement are less clear and appear subtler than estrogen’s impact in women (Bawor et al., 2015). In opioid-use disorder, any opioid intake markedly reduces or suppresses testosterone in men but not in women (Bawor et al., 2015), underscoring sex-specific regulation of the hypothalamic–pituitary–gonadal axis and its hormones GnRH, LH, and FSH (Katz & Mazer, 2009). Resulting mood, stress reactivity, aggression, and libido

changes tied to testosterone fluctuations can therefore trigger markedly different responses in male versus female opioid users (Börjesson et al., 2011; Fullerton et al., 2018; Smith & Elliott, 2012).

Understanding the biological determinants of vulnerability to addiction can be very useful in developing psychoeducational programs and interventions aimed at prevention and treatment. Although biological factors help explain some of the differences in addiction vulnerability, a comprehensive understanding of why certain individuals initiate and sustain substance use is possible only when psychosocial determinants are also taken into account.

Sex, Gender, And Social Expectations

Over the past decades, substance-use disorder (SUD) research has moved toward a more holistic perspective that, in addition to biological determinants, also considers psychological and social factors to understand vulnerability to addiction. Within this framework, sex and gender emerge as essential analytical categories for explaining the differences seen in epidemiological trends, patterns of use, clinical presentations, and access to treatment (Becker & Koob, 2016; Fonseca et al., 2021; Greenfield et al., 2010). Sex differences refer to genetically determined biological characteristics, whereas gender refers to the socially constructed and variable roles, norms, expectations, and behaviors associated with men, women, and non-binary people (Kaufman et al., 2023; World Health Organization, 2011). These norms are deeply embedded in social structures and have evolved over time. In the realm of addiction, gender expectations play a crucial role in vulnerability to substance use and in the development of alcohol-use disorder (AUD), influencing both the decision to consume and access to treatment.

According to the World Health Organization (2011), gender norms affect not only people’s emotional and social experiences but also their mental and physical health. Social pressures linked to gender roles may therefore lead men and women to experience exposure to substances, the progression of use, and treatment responses differently (Harris et al., 2022). Historically, substance use has been more prevalent among men, which has led to addiction services, research, and policies that are male-centered or “gender-neutral,” leaving the specific needs of women and other gender identities unaddressed (Fonseca et al., 2021; Harris et al., 2022; Meyer et al., 2019; Torrens-Melich et al., 2021). Scientific literature indicates that the gender gap in SUDs is narrowing for certain substances and age groups, an alarming trend when psychosocial and clinical settings do not adequately recognize or meet differentiated needs.

Beyond the biological-sex vulnerabilities described in the previous section, social expectations grounded in gender shape consumption behaviors. Social dynamics,

especially interpersonal relationships and community contexts, strongly influence men's and women's patterns of use, because traditional norms assign specific roles to each gender. Men are typically linked to protection and provider roles within the family, characterized by competitiveness, confidence, and persistence; women, to reproductive, caregiving, and emotional-support roles, with traits such as dedication, expressiveness, and empathy (Sánchez-López, 2013; Sánchez-López & Limiñana-Gras, 2017).

Conformity to these norms, however, varies with contextual and individual factors, producing different degrees of adherence or resistance (Sánchez-López et al., 2014).

Femininity and masculinity thus play a significant role in addiction vulnerability. Femininity encompasses the culturally defined traits, behaviors, and roles considered proper for women, shaping expectations about how they should think, feel, and act (Mahalik et al., 2005). In Western societies, normative femininity idealizes, among other qualities, caregiving, emotional expressiveness, and concern with appearance (Levant et al., 2007; Mahalik et al., 2005). Adherence varies across racial and cultural groups: for example, Latin culture values subordination and self-sacrifice; the "strong Black woman" stereotype emphasizes resilience; Asian hyper-femininity prizes docility and reliability (Castillo et al., 2010; Donovan & West, 2014). These norms shape behavior and can create differential risks for substance use (Kulis et al., 2008); understanding vulnerability therefore demands an intersectional approach that integrates gender, ethnicity, and cultural expectations.

A recent systematic review showed that femininity significantly influences within-group variations in women's substance use: 74 % of the studies ($n = 17$) found that endorsement of feminine norms accounted for a unique portion of variance in consumption (Brady et al., 2016). Although substance use has traditionally been linked to masculinity (Van Gundy et al., 2005), recent research also connects feminine norms to use (Iwamoto et al., 2016). Engaging in stereotypically masculine behaviors such as drinking can be associated, for many women, with empowerment, pleasure, and peer approval (Lyons & Willott, 2008). While femininity often promotes health-seeking behaviors (e.g., getting help) (Shakya et al., 2019), some traits today may increase risk (Kaya et al., 2016). Examining how femininity shapes consumption is essential, as women frequently use substances to manage emotional distress (Dragan, 2015) and are vulnerable to gender-role stress; they often turn to substances to cope with emotional or physical pain and to self-medicate mental-health problems, frequently in response to traumatic experiences (National Institute on Drug Abuse, 2020; Stone et al., 2021).

Additionally, women are at greater risk than men of being introduced to drug use by their partners, suggesting

an initiation pattern shaped by intimate relationships and co-dependence (Mburu et al., 2019). Rigid adherence to feminine norms can generate dissatisfaction, devaluation, and shame, raising the likelihood of substance use as a coping strategy (Efthim et al., 2011; Hoffman, 2001). Conversely, a strong identification with traditional femininity may deter some women, as substance use conflicts with expected "proper" behavior (Iwamoto et al., 2018).

Research on substance use often focuses on how femininity or minority identities (e.g., women, LGBTQ+ individuals) shape vulnerability, while the influence of masculinity norms remains underexplored. However, many men engage in substance use to align with ideals of toughness, suppress emotions, or respond to social pressures tied to hegemonic masculinity (Klingemann & Klingemann, 2023). Overlooking this perspective limits the understanding of substance use among men. Integrating gender roles into interventions may enhance both their effectiveness and contextual relevance.

Social factors and expectations can also act as protective elements. Women are generally less exposed than men to drug- or alcohol-centered social environments and tend to form close, supportive relationships, which foster psychological resilience (McHugh et al., 2018). Caregiving responsibilities, that sometimes become barriers, can likewise motivate treatment seeking, particularly efforts to maintain or regain child custody (Greenfield et al., 2007; Sword et al., 2009).

Finally, stigma is a key factor that profoundly shapes experiences and outcomes, especially for women. Women with addictions face dual stigma: for their dependence and for violating gender norms of self-control and responsibility (Howard, 2015). This stigma can prompt concealment or delayed help-seeking.

Regarding people whose sexual orientation is non-normative (gay, lesbian, and bisexual individuals), recent evidence indicates that substance-use risk is patterned by sexual identity rather than by sex alone. Lesbian and bisexual women display elevated rates of alcohol- and drug-related disorders, whereas gay and bisexual men are more likely to use illicit drugs and encounter related problems (Green & Feinstein, 2012).

These disparities appear to be shaped by sociocultural factors, such as affiliation with gay culture or HIV status, and are not mitigated by demographic characteristics like female sex or older age (Green & Feinstein, 2012). In fact, bisexual orientation is consistently linked to the highest substance-use risk: bisexual women engage in more forms of use than lesbian or gay women, and no substance-use domain shows lower risk for bisexuals (Schuler & Collins, 2020; Schuler et al., 2018).

As for gender-nonconforming individuals, the determinants are somewhat more complex and will be explained in the next section.

Vulnerability In Gender-Nonconforming Individuals

Among gender-nonconforming people, that is, individuals whose gender identity differs from their sex assigned at birth, sex and gender issues become fundamental and even defining when it comes to vulnerability to addiction. Recent studies show that transgender and non-binary (TNB) individuals have higher prevalence rates of alcohol, tobacco, cannabis, and psychostimulant use, as well as greater involvement in chemsex practices, than their cisgender peers (Cotaina et al., 2022; Scheim et al., 2017). For instance, Scheim et al. (2017) estimated in a Canadian sample that 12 % of TNB people had used at least one high-risk drug in the preceding year, particularly cocaine and amphetamines, a proportion higher than in the general population. Likewise, a recent meta-analysis determined that identifying as TNB roughly doubled the odds of tobacco and drug use compared with cisgender individuals, although no significant differences were found for alcohol use (Cotaina et al., 2022). In addition, analysis of thousands of U.S. medical records revealed higher rates of nicotine, alcohol, and drug-abuse diagnoses in TNB patients than in cis patients (Kidd et al., 2023). Collectively, these data underscore that TNB people bear a disproportionate burden of problematic substance use relative to the cisgender population, making them more vulnerable.

Research has often focused on transgender women, those assigned male at birth, particularly in socially vulnerable contexts and has confirmed high prevalence of methamphetamine and cocaine use (Reback & Fletcher, 2014). In transgender women engaged in sex work, many reported recent methamphetamine or other stimulant use to prolong and enhance sexual encounters (Santos et al., 2014). Continuing the theme of substances used for sexual purposes, chemsex is especially relevant among TNB individuals and reveals differences even within this group; clinical data show stimulant-use rates up to ten times higher in transgender women than in transgender men (Gómez-Gil et al., 2012). However, a recent U.S. study by Kidd et al. (2023) concluded that there were no significant differences between transgender men and women regarding problematic substance use.

Why is this vulnerability higher? Several studies indicate that substance use among TNB people often serves as a coping strategy for chronic stress arising from discrimination, rejection, and trauma (Hendricks & Testa, 2012). TNB individuals frequently face stigma and prejudice in family school, workplace, and healthcare settings, as well as transfobic violence throughout life, all of which contribute to sustained experiences of social exclusion and chronic stress. Empirical evidence shows that transgender people who report higher levels of discrimination also present significantly elevated rates of recent substance

use and lifetime substance use disorders, highlighting the cumulative impact of chronic exposure to stigma and exclusion (Wolfe et al., 2021). Faced with insecurity, emotional stress, and perceived lack of support, substance use may emerge as self-medication (Bockting et al., 2013; Kidd et al., 2023). For example, transgender women with a history of sexual trauma or violence have significantly higher odds of using drugs like cocaine to cope with psychological pain (Budhwani et al., 2017). Similarly, in a U.S. study of 600 adult trans people, those who experienced frequent transfobic discrimination showed much higher rates of recent use, lifetime substance-use disorders, and likelihood of having needed treatment (Wolfe et al., 2021). These findings confirm that continual exposure to rejection and violence increases the risk of turning to psychoactive substances to manage stress and emotional distress (Hughto et al., 2021; Klein & Washington, 2024).

Another potentially decisive determinant of TNB vulnerability is the healthcare environment. Living in a cisnormative care system means that mental-health and addiction services were built on the premise that being cisgender is the norm and that being trans was historically classified as a disorder. Consequently, interventions were designed only for cisgender men or women, and even today many programs lack affirmative protocols for TNB people; only a few are specifically geared to the LGBTIQ+ population (Williams & Fish, 2020). A direct outcome of this binary approach is the lack of visibility of the non-binary community: non-binary individuals show poorer mental health than binary trans people, presumably because of the added stress of being invalidated or ignored by the healthcare system, and they report higher anxiety, depression, and risk behaviors than their binary peers (Klein & Washington, 2024; Reisner & Hughto, 2019; Thorne et al., 2019). Moreover, non-binary people have been excluded from many substance-use studies (Connolly & Gilchrist, 2020), further reinforcing their invisibility. A qualitative study in Argentina highlighted that the lack of trans-health education among providers is a main obstacle to appropriate care (Cordero & Saletti-Cuesta, 2025). Likewise, recent work by Jessani et al. (2024) noted insufficient preparation of healthcare teams to recognize and address the needs of transgender and gender-diverse people, especially outside major urban centers. In the face of this training deficit, various authors call for cultural-competence training and affirmative-practice models to improve care quality and reduce biases linked to underdiagnosis and undertreatment (Hughto et al., 2015; Korpaisarn & Safer, 2018), as repeated discrimination is associated with greater psychological distress, risk of depression, and substance abuse, factors that drive many TNB individuals away from formal services and lead to self-medication and self-care as survival strategies (Johnson et al., 2019; Schechner et al., 2025).

All these factors that heighten the vulnerability of TNB people to addiction mean that interventions must be adaptable to this population and attentive to its specific needs.

Sex, Gender And Dual Diagnosis

Psychiatric comorbidity among individuals with substance-use disorders (SUDs) is remarkably high, with prevalence estimates ranging from 50% to 80%, depending on the population studied (Andersson et al., 2023; Díaz-Fernández et al., 2023; Fernández-Miranda et al., 2024; Szman et al., 2022). The simultaneous presence of a SUD and another mental disorder is referred to as dual diagnosis (DD) (Fernández-Artamendi et al., 2024; Szman et al., 2022). The explanation with the strongest scientific backing is that both conditions share common neurobiological bases and genetic risk factors, while the toxic substances consumed alter many neurotransmission systems involved in the pathogenesis of these other mental disorders (Szman et al., 2022). Determining the primary diagnosis in DD cases is often complex. Most studies have focused on linking substance use to the development of psychiatric disorders; far fewer examine the reverse relationship, and fewer still incorporate a gender perspective.

The limited studies that do consider sex and gender as variables indicate that anxiety and affective disorders are more prevalent among women with DD (Díaz-Fernández et al., 2023; Szman et al., 2015). Anxiety is a significant risk factor for substance use, especially alcohol and cannabis (Prieto-Arenas et al., 2022). For instance, a study on social anxiety found a stronger association between this condition and alcohol-related problems in women than in men (Buckner et al., 2023). Similarly, panic disorder has been linked to a greater risk of developing alcohol dependence, about twice as high in women as in men (Chang et al., 2020). Gender differences have also been identified in patterns of psychiatric comorbidity and in the use of health services prior to the onset of alcohol dependence. Among young people, cannabis use has been described as a coping strategy for anxiety and low distress tolerance (Morris et al., 2024). Low distress tolerance is significantly associated with heavier cannabis use and related complications. Although women tend to report lower overall consumption, their use is more often motivated by the management of psychiatric symptoms (Arranz et al., 2020; Leadbeater et al., 2019).

Gender disparities are likewise evident in the comorbidity between psychotic disorders and SUDs. Patients with schizophrenia face a three-fold higher risk of developing cannabis-use disorder than the general population (Kozak et al., 2021). Even though women with schizophrenia display a lower substance-use prevalence (Gómez-Sánchez-Lafuente et al., 2022; Novick et al., 2016), substance misuse seems to have more detrimental long-term effects for them (Casanovas et al., 2023; van der Meer et al., 2015). Women

with schizophrenia and cannabis-use disorder typically experience more severe symptoms, more hospitalizations, and poorer treatment outcomes (Miquel et al., 2013) and are less likely to reduce cannabis use over time, worsening illness trajectory (Calakos et al., 2017; Casanovas et al., 2023).

The co-occurrence of a psychiatric disorder and a SUD is linked to more severe clinical symptoms and greater psychosocial dysfunction than is usually seen in individuals with a single disorder (Andersson et al., 2023; Mangrum et al., 2006), and this is especially pronounced in women with dual diagnosis. These women face multiple, interconnected vulnerabilities that complicate both clinical and social care. The literature shows that, compared with men with similar diagnoses, they are disproportionately affected by histories of trauma, gender-based violence, and abuse, which increases the risk of relapse, non-adherence, and poorer health outcomes (Fonseca et al., 2021; Meyer et al., 2019; Tirado-Muñoz, 2018; Torrens-Melich et al., 2021). In addition, the interaction between psychiatric symptoms and substance use hinders timely diagnosis and contributes to a higher likelihood of social exclusion, unemployment, stigmatization, and limited access to gender-responsive integrated services (McHugh et al., 2018).

Women with DD also suffer from triple stigma: for being women, for having a mental disorder, and for experiencing a SUD. This compounded stigma may foster shame, guilt, and isolation, decreasing the likelihood of seeking or staying in treatment (Calderón Calvo, 2021). Many also lack strong social and family support networks, key elements in recovery. Both internalized and social stigma not only reinforce negative stereotypes and prejudices but directly affect how these women access, use, and benefit from health services (McCartin et al., 2022).

Although the small number of gender-focused studies hampers analysis of sex differences in dual diagnosis, the lack of data on sexual orientation and gender identity poses an even greater challenge to understanding disparities and designing tailored interventions for LGBTIQ+ populations (Flentje et al., 2015). In this regard, 56 % of LGBTIQ+ youths met criteria for at least one mental-health or substance-use disorder in the past year, compared with 29 % of their cis-heterosexual peers (Kingsbury & Findlay, 2024).

This group not only shows disproportionately high rates of substance use and SUDs but is also more susceptible to severe mental-health problems, such as higher levels of anxiety, depression, suicidal ideation, and greater exposure to trauma and PTSD (Marchi et al., 2023). They also face higher vulnerability to infections such as HIV and HCV, especially in the context of high-risk behaviors related to chemsex. Structural and interpersonal factors, like discrimination, stigmatization, harassment, and internalized homophobia, worsen psychological distress and act as significant barriers to adequate care (Kidd et al., 2019; Marchi et al., 2024; Silveri et al., 2022).

Thus, transgender and gender-diverse individuals face increased vulnerability to substance use disorders due to structural factors such as exclusionary public policies, limited access to inclusive healthcare services, and stigmatizing social norms (Poteat et al., 2023). Recent legislative frameworks specifically target LGBTQ+ youth, increasing their risk of academic underachievement, suicide, and discrimination. Policies that restrict access to gender-affirming care create ethical dilemmas for professionals by limiting their ability to provide safe, evidence-based treatment (Kline et al., 2023). These structural determinants significantly hinder effective prevention and treatment of substance misuse within LGBTQ+ populations (Phillips et al., 2025).

Conclusions

The evidence synthesized in this review indicates that gendered constructs, femininity, masculinity to non-binary identities, shape neurobiological, psychological, and social vulnerability to substance-use disorders (SUDs) and their frequent psychiatric comorbidities (DD). Rigid adherence to normative roles heightens risk behaviors, whereas incongruence between lived identity and societal expectations drives stress, trauma exposure, and maladaptive coping through substance use. These findings demand prevention and treatment strategies that explicitly account for gender identity, expression, and intersectional determinants such as class, race, and sexual orientation.

Only by dismantling binary, cisnormative assumptions in research design, diagnostic criteria, and service delivery, culturally informed interventions that target the mechanisms linking gendered stressors to addiction trajectories can be generated.

Conflict of interest

All authors declare that they have no conflicts of interest.

Financial support

This work was supported by grants: PND2024-I037 and PND2024-I092 funded by Plan Nacional Sobre Drogas (Ministerio de Sanidad); RD24/0003/0004 and RD24/0003/0001 funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and Cátedra Género y Salud of the University of Valencia.

References

Allen, A. M., Weinberger, A. H., Wetherill, R. R., Howe, C. L. & McKee, S. A. (2019). Oral contraceptives and cigarette smoking: A review of the literature and future directions. *Nicotine & Tobacco Research: Official Journal*

of the Society for Research on Nicotine and Tobacco, 21(5), 592-601. <https://doi.org/10.1093/ntr/ntx258>

Andersson, H. W., Mosti, M. P. & Nordfjaern, T. (2023). Inpatients in substance use treatment with co-occurring psychiatric disorders: A prospective cohort study of characteristics and relapse predictors. *BMC psychiatry*, 23(1), 152. <https://doi.org/10.1186/s12888-023-04632-z>

Arranz, S., Mané, A., Bergé, D., Monserrat, C., Cabezas, A., Vilella, E. & Sanchez- Gistau, V. (2020). The impact of sex and cannabis on clinical features in first- admitted patients with psychosis. *European neuropsychopharmacology: The journal of the European College of Neuropsychopharmacology*, 36, 235–243. <https://doi.org/10.1016/j.euroneuro.2020.03.003>

Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Steiner, M., Anglin, R., Coote, M., Pare, G., Thabane, L. & Samaan, Z. (2015). Testosterone suppression in opioid users: A systematic review and meta-analysis. *Drug and Alcohol Dependence*, 149, 1-9. <https://doi.org/10.1016/j.drugalcdep.2015.01.038>

Becker, J. B. (2016). Sex differences in addiction. *Dialogues in Clinical Neuroscience*, 18(4), 395-402. <https://doi.org/10.31887/DCNS.2016.18.4/jbecker>

Becker, J. B. & Chartoff, E. (2019). Sex differences in neural mechanisms mediating reward and addiction. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, 44(1), 166-183. <https://doi.org/10.1038/s41386-018-0125-6>

Becker, J. B. & Koob, G. F. (2016). Sex differences in animal models: Focus on addiction. *Pharmacological Reviews*, 68(2), 242–263. <https://doi.org/10.1124/pr.115.011163>

Berlin, I., Gasior, M. J. & Moolchan, E. T. (2007). Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco- dependent smokers. *Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco*, 9(4), 493-498. <https://doi.org/10.1080/14622200701243193>

Bockting, W. O., Miner, M. H., Swinburne Romine, R. E., Hamilton, A. & Coleman, E. (2013). Stigma, mental health, and resilience in an online sample of the US transgender population. *American Journal of Public Health*, 103(5), 943–951. <https://doi.org/10.2105/AJPH.2013.301241>

Börjesson, G., Mårtensson, A., Holmer, H. I. & Westertling, D. (2011). F633 Low testosterone levels in men with long-term opioid treatment. *European Journal of Pain Supplements*, 5(S1), 178-178. [https://doi.org/10.1016/S1754-3207\(11\)70613-7](https://doi.org/10.1016/S1754-3207(11)70613-7)

Brady, J., Iwamoto, D. K., Grivel, M., Kaya, A. & Clinton, L. (2016). A systematic review of the salient role of femi-

- nine norms on substance use among women. *Addictive Behaviors*, 62, 83–90. <https://doi.org/10.1016/j.addbeh.2016.06.005>
- Buckner, J. D., Morris, P. E., Ferrie, M. L. & Scherzer, C. R. (2023). Social anxiety and alcohol use and related problems among black adults: Differential roles of motives by sex. *Substance Use & Misuse*, 58(1), 36–43. <https://doi.org/10.1080/10826084.2022.2137813>
- Budhwani, H., Hearld, K. R., Milner, A. N., Charow, R., McGlaughlin, E. M., Rodriguez-Lauzurique, M., Rosario, S. & Paulino-Ramirez, R. (2017). Transgender women's experiences with stigma, trauma, and attempted suicide in the Dominican Republic. *Suicide and Life-Threatening Behavior*, 48(6), 788–796. <https://doi.org/10.1111/sltb.12400>
- Calakos, K. C., Bhatt, S., Foster, D. W. & Cosgrove, K. P. (2017). Mechanisms Underlying Sex Differences in Cannabis Use. *Current addiction reports*, 4(4), 439–453. <https://doi.org/10.1007/s40429-017-0174-7>
- Calderón Calvo, C. (2021). El estigma en personas con patología dual como barrera de acceso y adherencia a recursos asistenciales. *Norte de Salud Mental*, 17(65), 34–47.
- Casanovas, F., Fonseca, F. & Mané, A. (2023). Substance use specificities in women with psychosis: A critical review. *Current neuropharmacology*, 21(9), 1953–1963. <https://doi.org/10.2174/1570159X21666221129113942>
- Castillo, L. G., Perez, F. V., Castillo, R. & Ghosheh, M. R. (2010). Construction and initial validation of the Marianismo Beliefs Scale. *Counselling Psychology Quarterly*, 23(2), 163–175. <https://doi.org/10.1080/09515071003776036>
- Chang, H. M., Pan, C. H., Chen, P. H., Chen, Y. L., Tai, M. H., Su, S. S., Tsai, S. Y., Chen, C. C. & Kuo, C. J. (2020). Sex differences in incidence and psychiatric comorbidity for alcohol dependence in patients with panic disorder. *Drug and alcohol dependence*, 207, 107814. <https://doi.org/10.1016/j.drugalcdep.2019.107814>
- Connolly, D. & Gilchrist, G. (2020). Prevalence and correlates of substance use among transgender adults: A systematic review. *Addictive Behaviors*, 111, 106544. <https://doi.org/10.1016/j.addbeh.2020.106544>
- Copenhaver, A. E. & LeGates, T. A. (2024). Sex-specific mechanisms underlie long-term potentiation at Hippocampus. Medium spiny neuron synapses in the medial shell of the nucleus accumbens. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 44(27), e0100242024. <https://doi.org/10.1523/JNEUROSCI.0100-24.2024>
- Cordero, M. L. & Saletti-Cuesta, L. (2025). Barreras y estrategias para la accesibilidad a la salud de las personas trans en Córdoba, Argentina. *Salud Colectiva*, 21, e5200. <https://doi.org/10.18294/sc.2025.5200>
- Cornish, J. L. & Prasad, A. A. (2021). Sex differences in substance use disorders: A neurobiological perspective. *Frontiers in Global Women's Health*, 2, 778514. <https://doi.org/10.3389/fgwh.2021.778514>
- Cosgrove, K. P., Wang, S., Kim, S.-J., McGovern, E., Nambusi, N., Gao, H., Labaree, D., Tagare, H. D., Sullivan, J. M. & Morris, E. D. (2014). Sex differences in the brain's dopamine signature of cigarette smoking. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 34(50), 16851–16855. <https://doi.org/10.1523/JNEUROSCI.3661-14.2014>
- Cotaina, M., Peraire, M., Boscá, M., Echeverría, I., Benito, A. & Haro, G. (2022). Substance use in the transgender population: A meta-analysis. *Brain Sciences*, 12(3), 366. <https://doi.org/10.3390/brainsci12030366>
- Díaz-Fernández, S., Miranda, J. J. F., Pastor, F. P. & Muñoz, F. L. (2023). Gender and addiction and other mental disorders comorbidity: Sociodemographic, clinical, and treatment differences. *Archives of women's mental health*, 26(5), 639–650. <https://doi.org/10.1007/s00737-023-01353-w>
- Donovan, R. A. & West, L. M. (2014). Stress and mental health: Moderating role of the strong black woman stereotype. *Journal of Black Psychology*, 41(4), 384–396. <https://doi.org/10.1177/0095798414543014>
- Dragan, M. (2015). Difficulties in emotion regulation and problem drinking in young women: The mediating effect of metacognitions about alcohol use. *Addictive Behaviors*, 48, 30–35. <https://doi.org/10.1016/j.addbeh.2015.04.008>
- Efthim, P. W., Kenny, M. E. & Mahalik, J. R. (2011). Gender role stress in relation to shame, guilt, and externalization. *Journal of Counseling & Development*, 79(4), 430–438. <https://doi.org/10.1002/j.1556-6676.2001.tb01990.x>
- Fernández-Artamendi, S., Florez Menéndez, G., Cortés-Tomás, M. T. & Pascual Pastor, F. S. (2024). Dual pathology? Reviewing the conceptualization of comorbidity in addictions. ¿Patología dual? Revisando la conceptualización de la comorbilidad en adicciones. *Adicciones*, 36(1), 3–10. <https://doi.org/10.20882/adicciones.2053>
- Fernández-Miranda, J. J., Fontoba-Díaz, J., Díaz-Fernández, S. & Pascual-Pastor, F. (2024). Co-occurrence of substance use disorders and other mental disorders in people undergoing specific treatment for any of them in Spain. Concurrencia de trastorno por consumo de sustancias y de otro trastorno mental en personas en tratamiento por alguno de ellos en España. *Adicciones*, 36(1), 31–40. <https://doi.org/10.20882/adicciones.1692>
- Flentje, A., Bacca, C. L. & Cochran, B. N. (2015). Missing data in substance abuse research? Researchers' reporting practices of sexual orientation and gender identity.

- Drug and alcohol dependence, 147, 280–284. <https://doi.org/10.1016/j.drugalcdep.2014.11.012>
- Fonseca, F., Robles-Martínez, M., Tirado-Muñoz, J., Alías-Ferri, M., Mestre-Pintó, J. I., Coratu, A. M. & Torrens, M. (2021). A gender perspective of addictive disorders. *Current Addiction Reports*, 8(1), 89–99. <https://doi.org/10.1007/s40429-021-00357-9>
- Fox, H. C., Sofuoglu, M., Morgan, P. T., Tuit, K. L. & Sinha, R. (2013). The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: Impact of gender and cue type. *Psychoneuroendocrinology*, 38(9), 1532–1544. <https://doi.org/10.1016/j.psyneuen.2012.12.022>
- Fullerton, E. F., Doyle, H. H. & Murphy, A. Z. (2018). Impact of sex on pain and opioid analgesia: A review. *Current Opinion in Behavioral Sciences*, 23, 183–190. <https://doi.org/10.1016/j.cobeha.2018.08.001>
- Gillies, G. E., Virdee, K., McArthur, S. & Dalley, J. W. (2014). Sex-dependent diversity in ventral tegmental dopaminergic neurons and developmental programming: A molecular, cellular and behavioral analysis. *Neuroscience*, 282, 69–85. <https://doi.org/10.1016/j.neuroscience.2014.05.033>
- Gómez-Gil, E., Zubiaurre-Elorza, L., Esteva, I., Guillaumon, A., Godás, T., Cruz Almaraz, M., Halperin, I. & Salameiro, M. (2012). Hormone-treated transsexuals report less social distress, anxiety and depression. *Psychoneuroendocrinology*, 37(5), 662–670. <https://doi.org/10.1016/j.psyneuen.2011.08.010>
- Gómez-Sánchez-Lafuente, C., Guzmán-Parra, J., Suarez-Perez, J., Bordallo-Aragon, A., Rodríguez-de-Fonseca, F. & Mayoral-Cleries, F. (2022). Trends in psychiatric hospitalizations of patients with dual diagnosis in Spain. *Journal of Dual Diagnosis*, 18(2), 92–100. <https://doi.org/10.1080/15504263.2022.2053770>
- Green, K. E. & Feinstein, B. A. (2012). Substance use in lesbian, gay, and bisexual populations: An update on empirical research and implications for treatment. *Psychology of addictive behaviors: Journal of the Society of Psychologists in Addictive Behaviors*, 26(2), 265–278. <https://doi.org/10.1037/a0025424>
- Greenfield, S. F., Brooks, A. J., Gordon, S. M., Green, C. A., Kropp, F., McHugh, R. K., ... Miele, G. M. (2007). Substance abuse treatment entry, retention, and outcome in women: A review of the literature. *Drug and Alcohol Dependence*, 86(1), 1–21. <https://doi.org/10.1016/j.drugalcdep.2006.05.012>
- Greenfield, S. F., Back, S. E., Lawson, K. & Brady, K. T. (2010). Substance abuse in women. *Psychiatric Clinics of North America*, 33 (2), 339–355. <https://doi.org/10.1016/j.psc.2010.01.004>
- Harris, M. T. H., Laks, J., Stahl, N., Bagley, S. M., Saia, K. & Wechsberg, W. M. (2022). Gender dynamics in substance use and treatment: A women's focused approach. *The Medical clinics of North America*, 106(1), 219–234. <https://doi.org/10.1016/j.mcna.2021.08.007>
- Hendricks, M. L. & Testa, R. J. (2012). A conceptual framework for clinical work with transgender and gender nonconforming clients: An adaptation of the minority stress model. *Professional Psychology: Research and Practice*, 43(5), 460–467. <https://doi.org/10.1037/a0029597>
- Hoffman, R. M. (2001). The measurement of masculinity and femininity: Historical perspective and implications for counseling. *Journal of Counseling and Development*, 79(4), 472–485. <https://doi.org/10.1002/j.1556-6676.2001.tb01995.x>
- Howard, H. (2015). Reducing stigma: Lessons from opioid-dependent women. *Journal of Social Work Practice in the Addictions*, 15(4), 418–438. <https://doi.org/10.1080/1533256X.2015.1091003>
- Hughto, J. M. W., Quinn, E. K., Dunbar, M. S., Rose, A. J., Shireman, T. I., Wintfeld, N. & Cahill, S. R. (2021). Prevalence and co-occurrence of substance use disorder diagnoses among US transgender adults. *JAMA Network Open*, 4(2), e2036512. <https://doi.org/10.1001/jamanetworkopen.2020.36512>
- Hughto, J. M. W., Reisner, S. L. & Pachankis, J. E. (2015). Transgender stigma and health: A critical review of stigma determinants, mechanisms, and interventions. *Social Science & Medicine*, 147, 222–231. <https://doi.org/10.1016/j.socscimed.2015.11.010>
- Iwamoto, D. K., Grivel, M., Cheng, A., Clinton, L. & Kaya, A. (2016). Asian American women and alcohol-related problems: The role of multidimensional feminine norms. *Journal of Immigrant and Minority Health*, 18, 687–695. <https://doi.org/10.1007/s10903-015-0159-3>
- Iwamoto, D. K., Corbin, W., Takamatsu, S. & Castellanos, J. (2018). The association between multidimensional feminine norms, binge drinking and alcohol-related problems among young adult college women. *Addictive behaviors*, 76, 243–249. <https://doi.org/10.1016/j.addbeh.2017.08.016>
- Jessani, A., Berry-Moreau, T., Parmar, R., Athanasakos, A., Prodger, J. L. & Mujugira, A. (2024). Healthcare access and experiences of transgender and gender diverse people in African countries: A systematic review. *BMC Global Public Health* 2(1), 44. <https://doi.org/10.1186/s44263-024-00073-2>
- Johnson, A. H., Hill, I., Beach-Ferrara, J., Rogers, B. A. & Bradford, A. (2019). Common barriers to healthcare for transgender people in the US South. *International Journal of Transgender Health*, 21(1), 70–78. <https://doi.org/10.1080/15532739.2019.1700203>
- Katz, N. & Mazer, N. A. (2009). The impact of opioids on the endocrine system. *The Clinical Journal of Pain*, 25(2), 170–175. <https://doi.org/10.1097/AJP.0b013e-3181850dff>

- Kaufman, M. R., Eschliman, E. L. & Karver, T. S. (2023). Differentiating sex and gender in health research to achieve gender equity. *Bulletin of the World Health Organization*, 101(10), 666–671. <https://doi.org/10.2471/BLT.22.289310>
- Kaya, A., Iwamoto, D. K., Grivel, M., Clinton, L. & Brady, J. (2016). The role of feminine and masculine norms in college women's alcohol use. *Psychology of Men & Masculinity*, 17(2), 206–214. <https://doi.org/10.1037/men0000017>
- Kidd, J. D., Levin, F. R., Dolezal, C., Hughes, T. L. & Bockting, W. O. (2019). Understanding predictors of improvement in risky drinking in a U.S. multi-site, longitudinal cohort study of transgender individuals: Implications for culturally- tailored prevention and treatment efforts. *Addictive behaviors*, 96, 68–75. <https://doi.org/10.1016/j.addbeh.2019.04.017>
- Kidd, J. D., Tettamanti, N. A., Kaczmarkiewicz, R., Corbeil, T. E., Dworkin, J. D., Jackman, K. B., Hughes, T. L., Bockting, W. O. & Meyer, I. H. (2023). Prevalence of substance use and mental health problems among transgender and cisgender U.S. adults: Results from a national probability sample. *Psychiatry Research*, 326, 115339. <https://doi.org/10.1016/j.psychres.2023.115339>
- Kingsbury, M. & Findlay, L. (2024). Mental health and access to support among 2SLGBTQ+ youth. *Health reports*, 35(11), 12–22. <https://doi.org/10.25318/82-003-x202401100002-eng>
- Klein, H. & Washington, T. A. (2024). Evidence of syndemic effects influencing older transgender persons' likelihood of contemplating suicide: Results from a large national study. *Aging & Mental Health*, 28(3), 1–11. <https://doi.org/10.1080/13607863.2023.2275153>
- Kline, N. S., Webb, N. J., Johnson, K. C., Yording, H. D., Griner, S. B. & Brunell, D. J. (2023). Mapping transgender policies in the US 2017–2021: The role of geography and implications for health equity. *Health & Place*, 80(102985), 102985. <https://doi.org/10.1016/j.healthplace.2023.102985>
- Klingemann, J. I. & Klingemann, H. (2023). Masculinity and addiction: A narrative review of therapeutic interventions for men with substance-use disorders. *Alkoholizm i narkomania*, 36(3), 207–220. <https://doi.org/10.5114/ain.2023.134777>
- Kokane, S. S. & Perrotti, L. I. (2020). Sex differences and the role of estradiol in mesolimbic reward circuits and vulnerability to cocaine and opiate addiction. *Frontiers in Behavioral Neuroscience*, 14, 74. <https://doi.org/10.3389/fnbeh.2020.00074>
- Komáreková, I., Straka, L., Novomeský, F. & Hejna, P. (2013). Gender differences in alcohol affection on an individual. *Soudni Lekarství*, 58(3), 36–38.
- Korpaisarn, S. & Safer, J. D. (2018). Gaps in transgender medical education among healthcare providers: A major barrier to care for transgender persons. *Reviews in Endocrine and Metabolic Disorders*, 19, 271–275. <https://doi.org/10.1007/s11154-018-9452-5>
- Kozak, K., H Smith, P., Lowe, D. J. E., Weinberger, A. H., Cooper, Z. D., Rabin, R. A. & George, T. P. (2021). A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. *The American journal of drug and alcohol abuse*, 47(5), 535–547. <https://doi.org/10.1080/00952990.2021.1946071>
- Kulis, S., Marsiglia, F. F., Lingard, E. C., Nieri, T. & Nagoshi, J. (2008). Gender identity and substance use among students in two high schools in Monterrey, Mexico. *Drug and alcohol dependence*, 95(3), 258–268. <https://doi.org/10.1016/j.drugalcdep.2008.01.019>
- Kvamme, T. L., Schmidt, C., Strelchuk, D., Chang-Webb, Y. C., Baek, K. & Voon, V. (2016). Sexually dimorphic brain volume interaction in college-aged binge drinkers. *NeuroImage: Clinical*, 10, 310–317. <https://doi.org/10.1016/j.nicl.2015.12.004>
- Leadbeater, B. J., Ames, M. E. & Linden-Carmichael, A. N. (2019). Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. *Addiction (Abingdon, England)*, 114(2), 278–293. <https://doi.org/10.1111/add.14459>
- Levant, R., Richmond, K., Cook, S., House, A. T. & Aupont, M. (2007). The Femininity Ideology Scale: Factor structure, reliability, convergent and discriminant validity, and social contextual variation. *Sex Roles: A Journal of Research*, 57(5–6), 373–383. <https://doi.org/10.1007/s11199-007-9258-5>
- Lyons, A. C. & Willott, S. A. (2008). Alcohol consumption, gender identities, and women's changing social position. *Sex Roles*, 59, 694–712. <https://doi.org/10.1007/s11199-008-9475-6>
- Mahalik, J. R., Morray, E. B., Coonerty-Femiano, A., Ludlow, L. H., Slattery, S. M. & Smiler, A. (2005). Development of the Conformity to Feminine Norms Inventory. *Sex Roles*, 52(7–8), 417–435. <https://doi.org/10.1007/s11199-005-3709-7>
- Mangrum, L. F., Spence, R. T. & Lopez, M. (2006). Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. *Journal of substance abuse treatment*, 30(1), 79–84. <https://doi.org/10.1016/j.jsat.2005.10.004>
- Marchi, M., Travascio, A., Uberti, D., De Micheli, E., Grenzi, P., Arcolin, E., Pingani, L., Ferrari, S. & Galeazzi, G. M. (2023). Post-traumatic stress disorder among LGBTQ people: A systematic review and meta-analysis. *Epidemiology and Psychiatric Sciences*, 32, e44. <https://doi.org/10.1017/S2045796023000586>
- Marchi, M., Travascio, A., Uberti, D., De Micheli, E., Quartaroli, F., Laquatra, G., Grenzi, P., Pingani, L.,

- Ferrari, S., Fiorillo, A., Converti, M., Pinna, F., Amadeo, F., Ventriglio, A., Mirandola, M., & Galeazzi, G. M. (2024). Microaggression toward LGBTIQ people and implications for mental health: A systematic review. *International Journal of Social Psychiatry*, 70(1), 23–35. <https://doi.org/10.1177/00207640231194478>
- Mburu, G., Limmer, M. & Holland, P. (2019). HIV risk behaviours among women who inject drugs in coastal Kenya: Findings from secondary analysis of qualitative data. *Harm reduction journal*, 16(1), 10. <https://doi.org/10.1186/s12954-019-0281-y>
- McCartin, M., Cannon, L. M., Harfmann, R. F., Dalton, V. K., MacAfee, L. K. & Kusunoki, Y. (2022). Stigma and reproductive health service access among women in treatment for substance use disorder. *Women's Health Issues*, 32(6), 595–601. <https://doi.org/10.1016/j.whi.2022.06.003>
- McHugh, R. K., Votaw, V. R., Sugarman, D. E. & Greenfield, S. F. (2018). Sex and gender differences in substance use disorders. *Clinical Psychology Review*, 66, 12–23. <https://doi.org/10.1016/j.cpr.2017.10.012>
- Meyer, J. P., Isaacs, K., El-Shahawy, O., Burlew, A. K. & Wechsberg, W. (2019). Research on women with substance use disorders: Reviewing progress and developing a research and implementation roadmap. *Drug and alcohol dependence*, 197, 158–163. <https://doi.org/10.1016/j.drugalcdep.2019.01.017>
- Miquel, L., Roncero, C., García-García, G., Barral, C., Daigre, C., Grau-López, L., Bachiller, D. & Casas, M. (2013). Gender differences in dually diagnosed outpatients. *Substance abuse*, 34(1), 78–80. <https://doi.org/10.1080/08897077.2012.709223>
- Morris, V. L., Owens, M. M., Syan, S. K., Petker, T. D., Sweet, L. H., Oshri, A., MacKillop, J. & Amlung, M. (2019). Associations between drinking and cortical thickness in younger adult drinkers: Findings from the Human Connectome Project. *Alcoholism: Clinical and Experimental Research*, 43(9), 1918–1927. <https://doi.org/10.1111/acer.14147>
- Morris, P. E., Vargo, L. A. & Buckner, J. D. (2024). Social anxiety and cannabis-related problems: The serial roles of distress tolerance and cannabis use motives. *Substance Use & Misuse*, 59(7), 1133–1140. <https://doi.org/10.1080/10826084.2024.2320400>
- National Institute on Drug Abuse. (2020). Substance use in women: Sex and gender differences in substance use. <https://nida.nih.gov/publications/research-reports/substance-use-women/sex-gender-differences-in-substance-use>
- Nie, L., Ghahremani, D. G., Mandelkern, M. A., Dean, A. C., Luo, W., Ren, A., Li, J. & London, E. D. (2021). The relationship between duration of abstinence and gray-matter brain structure in chronic methamphetamine users. *The American Journal of Drug and Alcohol Abuse*, 47(1), 65–73. <https://doi.org/10.1080/00952990.2020.1778712>
- Novick, D., Montgomery, W., Treuer, T., Moneta, M. V. & Haro, J. M. (2016). Sex differences in the course of schizophrenia across diverse regions of the world. *Neuropsychiatric disease and treatment*, 12, 2927–2939. <https://doi.org/10.2147/NDTS.101151>
- Peart, D. R., Andrade, A. K., Logan, C. N., Knackstedt, L. A. & Murray, J. E. (2022). Regulation of cocaine-related behaviours by estrogen and progesterone. *Neuroscience and Biobehavioral Reviews*, 135(104584), 104584. <https://doi.org/10.1016/j.neubiorev.2022.104584>
- Pfefferbaum, A., Rohlfing, T., Pohl, K. M., Lane, B., Chu, W., Kwon, D., Nichols, B. N., Brown, S. A., Tapert, S. F., Cummins, K., Thompson, W. K., Brumback, T., Meloy, M. J., Jernigan, T. L., Dale, A., Colrain, I. M., Baker, F. C., Prouty, D., De Bellis, M. D. & Sullivan, E. V. (2016). Adolescent development of cortical and white matter structure in the NCANDA sample: Role of sex, ethnicity, puberty, and alcohol drinking. *Cerebral Cortex*, 26(10), 4101–4121. <https://doi.org/10.1093/cercor/bhv205>
- Phillips, J. C., Cornelius, J. B., Neira, P. M., Hein, L., Ducar, D., Rose, C. D., Rosa, W. E., Ballout, S., Nagel, D. A., Millender, E. I. F., Neft, M. W., Jablonski, R. A., Murray, T. A., Stamps, D. C., Brous, E., & Keepnews, D. M. (2025). Advancing human rights, health equity, and equitable health policy with LGBTQ+ people: An American Academy of Nursing consensus paper. *Nursing Outlook*, 73(5), 102496. <https://doi.org/10.1016/j.outlook.2025.102496>
- Poteat, T., Davis, A. M. & Gonzalez, A. (2023). Standards of care for transgender and gender diverse people. *JAMA: The Journal of the American Medical Association*, 329(21), 1872–1874. <https://doi.org/10.1001/jama.2023.8121>
- Prieto-Arenas, L., Díaz, I. & Arenas, M. C. (2022). Gender differences in dual diagnoses associated with cannabis use: A review. *Brain sciences*, 12(3), 388. <https://doi.org/10.3390/brainsci12030388>
- Rando, K., Tuit, K., Hannestad, J., Guarnaccia, J. & Sinha, R. (2013). Sex differences in decreased limbic and cortical grey matter volume in cocaine dependence: A voxel-based morphometric study. *Addiction Biology*, 18(1), 147–160. <https://doi.org/10.1111/adb.12008>
- Reback, C. J. & Fletcher, J. B. (2014). HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. *AIDS and behavior*, 18(7), 1359–1367. <https://doi.org/10.1007/s10461-013-0657-z>
- Regner, M. F., Dalwani, M., Yamamoto, D., Perry, R. I., Sakai, J. T., Honce, J. M. & Tanabe, J. (2015). Sex differences in gray matter changes and brain-behavior relationships in patients with stimulant dependence.

- Radiology, 277(3), 801- 812. <https://doi.org/10.1148/radiol.2015142541>
- Reisner, S. L. & Hughto, J. M. W. (2019). Comparing the health of non-binary and binary transgender adults in a statewide non-probability sample. *PloS one*, 14(8), e0221583. <https://doi.org/10.1371/journal.pone.0221583>
- Sánchez-López, M. P. (2013). La salud desde la perspectiva de género: El estado de la cuestión. In M. P. Sánchez-López (Ed.), *La salud de las mujeres* (pp. 17–40). Madrid, España: Síntesis.
- Sánchez-López, M. P. & Limiñana-Gras, R. M. (2017). Health from a gender perspective. In M. P. Sánchez-López & R. M. Limiñana-Gras (Eds.), *The Psychology of Gender and Health* (pp. 1–52). London: Elsevier. <https://doi.org/10.1016/B978-0-12-803864-2.00001-8>
- Sánchez-López, M. P., Saavedra, A. I., Dresch, V. & Limiñana-Gras, R. M. (2014). Conformity to traditional gender norms in a feminized occupation: The influence on health behaviors. *Health*, 6(20), 2775–2789. <https://doi.org/10.4236/health.2014.620317>
- Santos, G. M., Rapues, J., Wilson, E. C., Macias, O., Parker, T. & Raymond, H. F. (2014). Alcohol and substance use among transgender women in San Francisco: Prevalence and association with human immunodeficiency virus infection. *Drug and Alcohol Review*, 33(3), 287–295. <https://doi.org/10.1111/dar.12116>
- Sardari, M., Mohammadpourmir, F., Hosseinzadeh Sahafi, O. & Rezayof, A. (2024). Neuronal biomarkers as potential therapeutic targets for drug addiction related to sex differences in the brain: Opportunities for personalized treatment approaches. *Progress in neuro-psychopharmacology & biological psychiatry*, 134, 111068. <https://doi.org/10.1016/j.pnpbp.2024.111068>
- Sawyer, K. S., Maleki, N., Papadimitriou, G., Makris, N., Oscar-Berman, M. & Harris, G. J. (2018). Cerebral white matter sex dimorphism in alcoholism: A diffusion tensor imaging study. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, 43(9), 1876-1883. <https://doi.org/10.1038/s41386-018-0089-6>
- Sawyer, K. S., Oscar-Berman, M., Barthelemy, O. J., Papadimitriou, G. M., Harris, G. J. & Makris, N. (2017). Gender dimorphism of brain reward system volumes in alcoholism. *Psychiatry Research. Neuroimaging*, 263, 15-25. <https://doi.org/10.1016/j.psychresns.2017.03.001>
- Schechner, J., Zayhowski, K., Haghighat, D. & Ruderman, M. (2025). Transgender and gender diverse patients' experiences with pregnancy-related genetics discussions: A qualitative study. *Journal of Genetic Counseling*, 34(2), e2018. <https://doi.org/10.1002/jgc4.2018>
- Schein, A. I., Bauer, G. R. & Shokoohi, M. (2017). Drug use among transgender people in Ontario, Canada: Disparities and associations with social exclusion. *Addictive Behaviors*, 72, 151–158. <https://doi.org/10.1016/j.adbeh.2017.03.022>
- Schuler, M. S. & Collins, R. L. (2020). Sexual minority substance use disparities: Bisexual women at elevated risk relative to other sexual minority groups. *Drug and alcohol dependence*, 206, 107755. <https://doi.org/10.1016/j.drugalcdep.2019.107755>
- Schuler, M. S., Rice, C. E., Evans-Polce, R. J. & Collins, R. L. (2018). Disparities in substance use behaviors and disorders among adult sexual minorities by age, gender, and sexual identity. *Drug and alcohol dependence*, 189, 139–146. <https://doi.org/10.1016/j.drugalcdep.2018.05.008>
- Shakya, H. B., Domingue, B., Nagata, J. M., Cislighi, B., Weber, A. & Darmstadt, G. L. (2019). Adolescent gender norms and adult health outcomes in the USA: A prospective cohort study. *The Lancet. Child & adolescent health*, 3(8), 529–538. [https://doi.org/10.1016/S2352-4642\(19\)30160-9](https://doi.org/10.1016/S2352-4642(19)30160-9)
- Silveri, G., Schimmenti, S., Prina, E., Gios, L., Mirandola, M., Converti, M. & Bragazzi, N. L. (2022). Barriers in care pathways and unmet mental health needs in LGB-TIQ+ communities. *International Review of Psychiatry*, 34(3–4), 215–229. <https://doi.org/10.1080/09540261.2022.2075256>
- Smith, H. S. & Elliott, J. A. (2012). Opioid-induced androgen deficiency (OPIAD). *Pain Physician*, 15(Suppl. 3), ES145-156.
- Stone, R., Campbell, J. K., Kinney, D. & Rothman, E. F. (2021). “He Would Take My Shoes and All the Baby’s Warm Winter Gear so We Couldn’t Leave”: Barriers to safety and recovery experienced by a sample of Vermont women with partner violence and opioid use disorder experiences. *Journal of Rural Health*, 37(1), 35–44. <https://doi.org/10.1111/jrh.12518>
- Sword, W., Jack, S., Niccols, A., Milligan, K., Henderson, J. & Thabane, L. (2009). Integrated programs for women with substance use issues and their children: A qualitative meta-synthesis of processes and outcomes. *Harm Reduction Journal*, 6, 32. <https://doi.org/10.1186/1477-7517-6-32>
- Szerman, N., Marín-Navarrete, R., Fernández-Mondragón, J. & Roncero, C. (2015). Patología dual en poblaciones especiales: Una revisión narrativa. *Revista internacional de investigación en adicciones*, 1(1), 50-67. <http://dx.doi.org/10.28931/riiad.2015.1.07>
- Szerman, N., Torrens, M., Maldonado, R., Balhara, Y. P. S., Salom, C., Maremmanni, I., Sher, L., Didia-Attas, J., Chen, J., Baler, R. & World Association on Dual Disorders (WADD) (2022). Addictive and other mental disorders: A call for a standardized definition of dual disorders. *Translational psychiatry*, 12(1), 446. <https://doi.org/10.1038/s41398-022-02212-5>

- Thibaut, F. (2018). Gender differences in addiction: Clinical implications. *Psychiatric Times*, 35(11), 17–18. <https://www.psychiatrictimes.com/view/gender-differences-addiction-clinical-implications>
- Thorne, N., Yip, A. K., Bouman, W. P., Marshall, E. & Arcelus, J. (2019). The terminology of identities between, outside and beyond the gender binary—A systematic review. *International Journal of Transgenderism*, 20(2–3), 138–154. <https://doi.org/10.1080/15532739.2019.1640654>
- Tirado-Muñoz, J., Gilchrist, G., Fischer, G., Taylor, A., Moskalewicz, J., Giammarchi, C. & Torrens, M. (2018). Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: A cross-sectional study. *Archives of Women's Mental Health*, 21(3), 259–269. <https://doi.org/10.1007/s00737-017-0800-3>
- Torrens-Melich, M., Orengo, T., Rodríguez de Fonseca, F., Almodóvar, I., Baquero, A. & Benito, A. (2021). Gender perspective in dual diagnosis. *Brain sciences*, 11(8), 1101. <https://doi.org/10.3390/brainsci11081101>
- Trillo, A. D., Merchant, R. C., Baird, J. R., Liu, T. & Nirenberg, T. D. (2012). Sex differences in alcohol misuse and estimated blood alcohol concentrations among emergency department patients: Implications for brief interventions. *Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine*, 19(8), 924–933. <https://doi.org/10.1111/j.1553-2712.2012.01408.x>
- van der Meer, F. J., Velthorst, E., Risk, G. & Group, P. (2015). Course of cannabis use and clinical outcome in patients with non-affective psychosis: A 3-year follow-up study. *Psychol. Med.*, 2015, 45(9), 1977–1988. <http://dx.doi.org/10.1017/S0033291714003092>
- Van Gundy, K., Schieman, S., Kelley, M. S. & Rebellon, C. J. (2005). Gender role orientations and alcohol use among Moscow and Toronto adults. *Social science & medicine* (1982), 61(11), 2317–2330. <https://doi.org/10.1016/j.socscimed.2005.07.033>
- Williams, N. D. & Fish, J. N. (2020). The availability of LGBT-specific mental health and substance abuse treatment in the United States. *Health services research*, 55(6), 932–943. <https://doi.org/10.1111/1475-6773.13559>
- Wolfe, H. L., Biello, K. B., Reisner, S. L., Mimiaga, M. J., Cahill, S. R. & Hughto, J. M. W. (2021). Transgender-related discrimination and substance use, substance use disorder diagnosis and treatment history among transgender adults. *Drug and alcohol dependence*, 223, 108711. <https://doi.org/10.1016/j.drugalcdep.2021.108711>
- World Health Organization. (2011). Gender mainstreaming for health managers: A practical approach. <https://apps.who.int/iris/handle/10665/44516>
- Zahr, N. M., Lenart, A. M., Karpf, J. A., Casey, K. M., Pohl, K. M., Sullivan, E. V. & Pfefferbaum, A. (2020). Multi-modal imaging reveals differential brain volumetric, biochemical, and white matter fiber responsivity to repeated intermittent ethanol vapor exposure in male and female rats. *Neuropharmacology*, 170(108066), 108066. <https://doi.org/10.1016/j.neuropharm.2020.108066>

